4b). Hence, even though CD8+ T cells from 8.3-NOD.Il21−/− mice show reduced proliferation to the cognate antigen, their ability to become cytolytic effector

cells upon antigen stimulation was not compromised. Adoptive transfer of polyclonal CD8+ T cells from Il21ra−/− NOD donors, along with IL-21Rα-deficient CD4+ T cells, failed to induce T1D in NOD.Scid recipients [9, 11], suggesting that homeostatic expansion alone is insufficient selleckchem to elicit the pathogenic potential of IL-21-deficient diabetogenic CD8+ T cells. However, the failure of Il21ra−/− to develop T1D could be reversed by the transfer of wild-type DCs [11]. These reports indicated that inefficient activation may underlie the inability of 8.3 T cells to cause disease in 8.3-NOD. Il21−/− mice. Given that IL-21 deficiency did not diminish the ability of 8.3 T cells to develop effector functions upon antigen stimulation (Fig. 4a,b) and to undergo homeostatic expansion (Fig. 3), we investigated whether previous antigen stimulation would enable 8.3 T cells to induce T1D in NOD.Scid mice. To this end, we stimulated IL-21-deficient and control 8.3 CD8+ T cells with the cognate peptide IGRP208–214 for

2 days before adoptive transfer to NOD.Scid recipients. NOD.Scid mice lack both NK T cells and CD4+ T cells, the major producers of IL-21 [15], and hence IL-21 is unlikely to be available to the activated donor cells. As shown in Fig. 4c, IL-21-deficient 8.3 CD8+ T cells stimulated by cognate antigen in vitro induced T1D in all NOD.Scid recipients within 10 days after adoptive transfer, as in the case of wild-type Z-VAD-FMK price donor cells. Even though the proportion of CD8+ T cells in the lymph nodes was reduced substantially in recipients of IL-21-deficient donor cells compared to recipients of wild-type cells (Fig. 4d), both groups of mice showed a similar level of islet infiltration (Fig. 4e) and developed T1D (Fig. 4c). To determine whether IL-21 produced

by donor cells is sufficient for T1D induction, we transferred splenocytes adoptively from diabetic NOD mice to NOD.Scid and NOD.Scid.Il21−/− recipients. As shown in Fig. 4f, both groups of recipient Nintedanib (BIBF 1120) mice developed T1D between 30 and 50 days after cell transfer, suggesting that IL-21 available from donor cells is sufficient for activated diabetogenic cells to induce disease. In addition, antigen-stimulated 8.3 T cells from IL-21-deficient mice caused diabetes in NOD.Scid.Il21−/− mice within 10 days (Fig. 4c). Collectively, the above results indicate that IL-21 is required for efficient activation of diabetogenic CD8+ T cells by antigen, but is dispensable during subsequent stages of islet destruction. Hence, the inability of 8.3-NOD.Il21/− to develop T1D is related most probably to the defective activation of 8.3 T cells by the endogenous autoantigen IGRP. As activation of naive T cells occurs first in draining lymph nodes, we investigated whether diabetogenic CD8+ T cells from 8.